Peoples Bank KS Sells 355 Shares of Sanofi (NASDAQ:SNY)

Peoples Bank KS lowered its stake in shares of Sanofi (NASDAQ:SNY) by 2.0% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 16,985 shares of the company’s stock after selling 355 shares during the quarter. Peoples Bank KS’s holdings in Sanofi were worth $819,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of SNY. Barrow Hanley Mewhinney & Strauss LLC boosted its stake in Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after acquiring an additional 3,164,092 shares during the last quarter. Magnetar Financial LLC raised its holdings in Sanofi by 1,153.1% in the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock worth $121,605,000 after purchasing an additional 2,306,286 shares during the period. Jennison Associates LLC boosted its position in shares of Sanofi by 938.0% during the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after purchasing an additional 1,720,972 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Sanofi by 28,890.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after buying an additional 1,424,289 shares during the period. Finally, Federated Hermes Inc. increased its position in shares of Sanofi by 26.5% in the 2nd quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock valued at $155,950,000 after buying an additional 673,172 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Trading Up 1.4 %

SNY opened at $49.87 on Wednesday. The stock has a market capitalization of $126.56 billion, a P/E ratio of 25.44, a P/E/G ratio of 1.23 and a beta of 0.57. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The firm’s fifty day simple moving average is $48.95 and its 200 day simple moving average is $52.11.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.55 earnings per share. As a group, research analysts anticipate that Sanofi will post 4.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Sanofi currently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.